Mabwell's Nectin-4-targeting antibody drug conjugate 9MW2821, combined with toripalimab, demonstrated an 83% objective response rate in locally advanced or metastatic urothelial carcinoma, with 74.5% confirmed response and a median progression-free survival of 12.9 months. A separate Phase II perioperative study in muscle-invasive bladder cancer showed 66.7% pathological complete response following neoadjuvant therapy, positioning the drug as a potential advance in treatment-resistant urologic malignancies.
Key Points
- 83% ORR and 12.9-month median PFS in combination urothelial carcinoma trial
- 66.7% pathological complete response in perioperative bladder cancer cohort
- No new safety signals observed; multiple regulatory fast-track designations
Longevity Analysis
This therapeutic advance addresses a major source of systemic morbidity and mortality in aging populations. Nectin-4 targeting represents a mechanistic approach to eliminating chemotherapy-resistant cancer cells through antibody-drug conjugate technology, allowing for selective targeting and reduced off-target toxicity compared to conventional cytotoxic approaches. The sustained response durability and pathological downstaging rates suggest potential to preserve organ function and quality of life in older patients with invasive bladder cancer, where standard treatment often compromises urinary and sexual function. As immunotherapy combinations become standard in oncology, this data supports a rational sequencing strategy for combination regimens in the context of cancer prevention and longevity optimization.
Original published by Longevity.Technology.